← Eichor
Study identifier: NCT06823895 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pharmacokinetic Study of Oligonucleotides in Maixuekang Capsules

Condition: Healthy  ·  Sponsor: Nanfang Hospital, Southern Medical University

PhasePhase 1
Planned participants12
Who can joinAll sexes, 18 Years to 45 Years
Healthy volunteersYes

About this study

The objective of this clinical trial is to learn the sequence and expression level of Maixuekang oligonucleotides in the plasma of healthy volunteers. 1. Detecting the sequence and expression levels of oligonucleotides in the blood of healthy subjects before and after a single administration of Maixuekang at different time points. 2. Detecting the sequence and expression levels of oligonucleotides in the blood of healthy subjects before and after multiple administrations of Maixuekang at different time points. Single dose group: Participants will be given Maixuekang capsules once, 1g, orally. Multiple dose group: Participants will receive 1g of Maixuekang capsules orally for 3 days, 3 times a day.

This description comes directly from the study's public registry record.

Talk to the study team

Pan  ·  +8613078891070  ·  huiyun1227@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06823895